Yao, Y.*, Simes ML*, Ying W, Zhao Q, Winkler A, Shukla S, Gray F, Nikolaidis C, Hewett G, Grembecka J, Cierpicki T. Development of PRC1 inhibitors employing fragment-based approach and NMR-guided optimization. Journal of Medicinal Chemistry 2025.

Shukla, S.*, Ying, W.*, Gray, F.*, Yao, Y.*, Simes, M. L.*, Zhao, Q., Miao, H., Cho, H. J., González-Alonso, P., Winkler, A., Lund, G., Purohit, T., Kim, E., Zhang, X., Ray, J. M., He, S., Nikolaidis, C., Ndoj, J., Wang, J., Jaremko, Ł., Jaremko, M., Ryan, R. J. H., Guzman, M. L., Grembecka, J. & Cierpicki, T. Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. Nature Chemical Biology 17, 784-793, (2021).(*Equal contribution)

Zhang, K.*, Liu, Z.*, Yao, Y.*, Qiu, Y., Li, F., Chen, D., Hamilton, D. J., Li, Z. & Jiang, S. Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC). Journal of Medicinal Chemistry 64, 4020-4033, (2021).(*equal contribution)

Zhang, W.*, Zhang, K.*, Yao, Y.*, Liu, Y., Ni, Y., Liao, C., Tu, Z., Qiu, Y., Wang, D., Chen, D., Qiang, L., Li, Z. & Jiang, S. Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer. Eur. J. Med. Chem., 113022, (2020). (*equal contribution)

Zhang, K.*, Yao, Y.*, Tu, Z., Liao, C., Wang, Z., Qiu, Y., Chen, D., Hamilton, D. J., Li, Z. & Jiang, S. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells. Future Med. Chem. 12, 311-323, (2020). (*equal contribution)

Jin, Y., Yao, Y., Chen, L., Zhu, X., Jin, B., Shen, Y., Li, J., Du, X., Lu, Y., Jiang, S. & Pan, J. Depletion of γ-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with imatinib. Theranostics 6, 1947-1962, (2016).

Yao, Y., Tu, Z., Liao, C., Wang, Z., Li, S., Yao, H., Li, Z. & Jiang, S. Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities. J. Med. Chem. 58, 7672-7680, (2015).

Yao, Y., Li, Z., Qiu, Y., Bai, J., Su, J., Zhang, D. & Jiang, S. Unprecedented reactions: from epichlorohydrin to epoxyglycidyl substituted divinyl ether and its conversion into epoxyglycidyl propargyl ether. Sci. Rep. 5, 14231pp., (2015).

Ma, N.*, Yao, Y.*, Zhao, B.-X., Wang, Y., Ye, W.-C. & Jiang, S. Total synthesis of securinega alkaloids (-)-norsecurinine, (-)-niruroidine and (-)-flueggine A. Chem. Commun. (Cambridge, U. K.) 50, 9284-9287, (2014). (*equal contribution)

Yao, Y., Liao, C., Li, Z., Wang, Z., Sun, Q., Liu, C., Yang, Y., Tu, Z. & Jiang, S. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. Eur. J. Med. Chem. 86, 639-652, (2014).

Su, J., Qiu, Y., Ma, K., Yao, Y., Wang, Z., Li, X., Zhang, D., Tu, Z. & Jiang, S. Design, synthesis, and biological evaluation of largazole derivatives: alteration of the zinc-binding domain. Tetrahedron 70, 7763-7769, (2014).

Zhu, X., Chen, L., Jiang, S., Chen, C., Yao, Y., Chen, D., Xue, H. & Pan, J. PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells. Cancer Biol. Ther. 15, 119-127, (2014).

Sun, Q., Yao, Y., Liu, C., Li, H., Yao, H., Xue, X., Liu, J., Tu, Z. & Jiang, S. Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry. Bioorg. Med. Chem. Lett. 23, 3295-3299, (2013).

Li, X., Tu, Z., Li, H., Liu, C., Li, Z., Sun, Q., Yao, Y., Liu, J. & Jiang, S. Biological evaluation of new largazole analogues: Alteration of macrocyclic scaffold with Click chemistry. ACS Med. Chem. Lett. 4, 132-136, (2013).

Su, K., Qiu, Y., Yao, Y., Zhang, D. & Jiang, S. 8-hydroxyquinoline-N-oxide-promoted copper-catalyzed C-S cross-coupling of thiols with aryl iodides. Synlett 23, 2853-2857, (2012).

Hao, J., Chen, B., Yao, Y., Hossain, M., Nagatomo, T., Yao, H., Kong, L. & Sun, H. Practical access to four stereoisomers of naftidrofuryl and their binding affinity towards 5-hydroxytryptamine 2A receptor. Bioorg. Med. Chem. Lett. 22, 3441-3444, (2012).

Cierpicki, T., Grembecka, J., Ying, W., Yao, Y., Gray, F. & Zhao, Q. Preparation of pyrrole derivatives as PRC1 inhibitors and methods of treatment therewith. WO2019236957A1 (2019).

Jiang, S., Tu, Z., Hao, H., Yao, Y., Qiu, Y., Yao, H., Qiang, L. & Chen, D. Preparation of Benazepine aromatic ring compounds as antitumor agents. CN107674059A (2018).

Jiang, S., Tu, Z., Hao, H., Yao, H., Qiu, Y., Yao, Y. & Chen, D. Preparation of heterocyclic urea compounds as anticancer agents. WO2018133716A1 (2018).

Jiang, S., Tu, Z., Zhu, J., Yao, H., Yao, Y., Qin, X., Gu, S. & Qiu, Y. Preparation of 2-amino-4-phenyl-6-(alkylamino)pyrimidine derivatives useful as anticancer agents. CN106928192A (2017).

Jiang, S., Tu, Z., Hao, H., Yao, H., Qiu, Y., Yao, Y. & Chen, D. Preparation of heterocyclic urea compounds as anticancer agents. CN106866571A (2017).

Jiang, S., Tu, Z., Zheng, D., Qin, D., Bai, J., Qin, X., Yao, Y., Liu, Y., Qiu, Y. & Chen, J. Preparation of 3-(pyridin-3-yl)acrylamide derivatives as nicotinamide phosphoribosyltransferase inhibitors useful for the treatment of cancer. WO2016095581A1 (2016).

Jiang, S., Yao, Z., Yao, Y., Qiu, Y., Lu, C., Su, K. & Yao, X. Cyclic peptide compound, and preparation method, pharmaceutical composition and use thereof. WO2015027959A1 (2015).

Jiang, C., Tu, Z., Zheng, D., Qin, D., Bai, J., Qin, X., Yao, Y., Liu, Y., Qiu, Y. & Chen, J. Preparation of 3-(pyridin-3-yl)acrylamide derivatives as nicotinamide phosphoribosyltransferase inhibitors useful for the treatment of cancer. CN104557863A (2015).

Jiang, S., Yao, Z., Yao, Y., Qiu, Y., Lu, C., Su, K. & Yao, X. Cyclopeptide compound, and preparation method, pharmaceutical combination and application thereof. CN103524598A (2014).

Jiang, S., Tu, Z., Li, X., Yao, Y. & Qiu, Y. Preparation of largazole analog compounds as antitumor agents. CN103601742A (2014).

Jiang, S., Tu, Z., Sun, Q., Liu, C., Yao, Y. & Qiu, Y. Preparation of N-containing heterocyclic derivatives as histone deacetylase I inhibitor. CN103086971A (2013).

Jiang, S., Li, S., Yao, Z., Yao, Y., Zhang, F., Chao, Y., Ye, H. & Chen, M. Preparation of cyclopeptides as histone deacetylase inhibitors. WO2013071715A1 (2013).

Jiang, S., Tu, Z., Yao, Y., Liu, C., Yao, H. & Xue, X. Preparation of triazole compounds as histone deacetylase inhibitors. CN102311398A (2012).

Jiang, S., Li, S., Yao, Y., Zhang, F., Chao, Y., Ye, H. & Chen, M. Preparation of cyclopeptides as histone deacetylase inhibitors. CN102391359A (2012).

Jiang, S., Xu, J., Li, S., Yao, H., Zeng, X. & Yao, Y. Process for preparation of FK228. CN102276689A (2011).